Cartine (Levocarnitine) is a prescription metabolic agent used to address metabolic deficits. This therapy is relevant for easing symptoms related to systemic imbalance and supports patients during episodes of heightened discomfort.

It is applied across domains where additional symptomatic support is needed, primarily in conditions characterized by a primary carnitine deficiency, certain inborn errors of metabolism (such as propionic acidemia), and the secondary deficiency seen in patients undergoing long-term hemodialysis for end-stage renal disease (ESRD).

The medication plays a role in managing complex symptom clusters that interfere with daily functioning, including profound muscle weakness, chronic fatigue, and cardiomyopathy (heart muscle weakness) associated with the energy deficit. It may also assist in reducing the risk of acute metabolic crises that create noticeable physiological strain.

“This therapy is used for managing conditions marked by increased physiological stress, helping to maintain a sense of stability when symptoms are more noticeable.”

---

Quick Fact: Relief for Systemic Energy Deficits

Primary Focus	Managing symptoms linked to profound muscle weakness and cardiac dysfunction in deficiency states.
Key Benefit	Supports the patient during difficult episodes by easing the impact of symptoms on routine activities.
Clinical Scenario	Relevant in clinical settings that require chronic support for symptom management and support during acute crises.

Official Eligibility Status: Who Can and Cannot Use Cartine?

Eligibility for Cartine (Levocarnitine) is defined by regulatory documents based on patient characteristics and pre-existing conditions.

---

Absolute Contraindications

Cartine is prohibited for use in patients with a known hypersensitivity or severe allergic reaction to the active ingredient, Levocarnitine, or any other component of the formulation. Additionally, oral solutions containing Sorbitol are contraindicated in patients with hereditary fructose intolerance.

---

Restricted and Conditional Use

Population Group	Eligibility Status or Restriction
Severe Renal Impairment	Chronic administration of high oral doses is not recommended due to metabolite accumulation; the injectable form is approved for patients on chronic dialysis.
Seizure Disorder	Use requires close monitoring, as the medicine may exacerbate pre-existing seizure activity.
Diabetes Mellitus	Patients receiving blood sugar-lowering agents require careful plasma glucose monitoring due to the risk of hypoglycemia.
Pregnancy and Lactation	Use is permitted only if clearly needed (lacking adequate human studies). A decision to discontinue nursing or treatment is required while breastfeeding.

---

Age Group Eligibility

Use is established and permitted across all age groups, including infants and children, for treating documented carnitine deficiencies. Geriatric patients typically require no specific dose adjustment based on age alone.

Interactions with other medicines and products

This section summarizes the official interaction profile for Cartine (Levocarnitine), based strictly on documentation from government regulatory sources.

Interaction Entity Map (High-Level)

Category	Official Interaction Statement or Entity
Interacting Medicines	Coumarinic Anticoagulants; Insulin and Oral Hypoglycaemic Treatments.
Mechanistic Basis	Pharmacodynamic interaction (documented effects on anticoagulation and glucose utilization).
Accumulation Risk	Severe Renal Impairment (including ESRD on dialysis) when taking high-dose oral levocarnitine.

Official Regulatory Statements

• Co-administration with coumarinic anticoagulants (e.g., Warfarin, Acenocoumarol) has been associated with reports of an increased International Normalised Ratio (INR).
• A pharmacodynamic interaction exists with Insulin and Oral Hypoglycaemic Agents that may result in hypoglycaemia (low blood sugar).
• The chronic administration of high oral doses in patients with severe renal impairment is associated with the accumulation of the inactive metabolites trimethylamine (TMA) and trimethylamine-N-oxide (TMAO).
• The oral solution is required to be consumed slowly and administered in doses that are spaced evenly throughout the day to manage tolerance.

Connection to the overall interaction profile

The regulatory profile is structured around monitoring requirements for agents that modify coagulation or blood glucose levels. The profile includes an explicit, population-specific restriction regarding the oral route of administration due to the risk of metabolite accumulation in patients with compromised renal function. Furthermore, mandatory rules for timing and consumption rate are defined for the oral solution to manage gastrointestinal tolerance.

Cartine is L-carnitine, an amino acid derivative that functions as a biological transport molecule. Its primary action is to facilitate the flux of long-chain fatty acids (LCFAs) across the inner mitochondrial membrane in tissues with high energy demand, such as the skeletal and cardiac muscle. This process is mediated by the carnitine palmitoyltransferase (CPT) system.

Specifically, Carnitine Palmitoyltransferase I (CPT I), an enzyme on the outer mitochondrial membrane, catalyzes the transfer of the acyl group from LCFAs (bound to Coenzyme A) to L-carnitine, forming an acylcarnitine compound. This acylcarnitine is subsequently translocated into the mitochondrial matrix by the carnitine-acylcarnitine translocase (CACT). Once inside the matrix, Carnitine Palmitoyltransferase II (CPT II), on the inner mitochondrial membrane, converts the acylcarnitine back into L-carnitine and acyl-CoA. The resulting acyl-CoA is the substrate that enters the beta-oxidation pathway, the intracellular cascade that ultimately leads to the generation of acetyl-CoA and subsequent ATP synthesis via the citric acid cycle. Additionally, L-carnitine exports excess acyl groups from the mitochondrial matrix, preventing the accumulation of toxic organic acids and maintaining cellular acyl-CoA/CoA homeostasis.

How to Use Cartine: Official Administration Guidelines

The usage of Cartine (Levocarnitine) is strictly guided by the official instructions for its approved oral and intravenous forms. Dosing is highly individualized and relies on titration based on a patient’s specific condition and laboratory values.

---

Administration Scope

Instruction	Official Guideline
Route of Administration	Oral (tablets/solution) for chronic therapy, and Intravenous (IV) for acute metabolic crises or patients on hemodialysis.
Standard Oral Dosing	The typical adult range is 1 to 3 g/day in divided doses. Oral solution dosage should begin at 1 g/day and be slowly increased.
IV Dosing (Acute)	The dose is 50 mg/kg given as a slow 2 - to 3 -minute bolus or by infusion, with subsequent doses administered every 3 to 6 hours in acute crisis.
Timing in Relation to Meals	Oral doses must be administered during or following meals and consumed slowly to enhance tolerance.
Age-Group Rules	The recommended pediatric dose is 50 to 100 mg/kg/day in divided doses, not to exceed 3 g/day.

---

Procedural Structure and Constraints

The administration of Cartine is highly procedural, defined by the following requirements:

• Dose Titration: Treatment requires slowly increasing the dose from the initial starting amount while monitoring tolerance and therapeutic response.
• Monitoring: The official protocol requires periodic measurement of plasma free carnitine concentrations (with a general target range of 35 to 60 mu mol/L) and blood chemistries to guide dose adjustments.
• Route Restriction: The oral solution is not for parenteral use. Conversely, the IV dose for hemodialysis patients (10 to 20 mg/kg) is given as a bolus after each dialysis session.

These instructions formalize a standardized, long-term protocol characterized by careful dosage management and continuous laboratory oversight, regardless of the administration route.

Research Evidence: Overview of Studies for Cartine (Levocarnitine)

Evidence for Use in Primary Carnitine Deficiency

Research for primary carnitine deficiency, a severe and rare inherited metabolic disorder, has been conducted in specialized settings. This evidence is primarily gathered from case reports, case series, and long-term regulatory reviews of clinical experience. Research explored endpoints such as cardiac function and severe muscle weakness (hypotonia), and studies monitored biochemical markers, such as plasma free carnitine levels. Findings describe patterns observed in the studies related to the stabilization of biochemical markers and changes measured during the study period for severe symptoms. Evidence derived from these specialized settings contributes to the understanding of this condition.

Evidence for Use in Secondary Deficiency in Long-term Hemodialysis (ESRD)

For patients undergoing long-term hemodialysis due to end-stage renal disease (ESRD), numerous Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews have been conducted. Research examined the compound's effect on outcomes related to systemic or functional imbalance, including muscle strength, chronic fatigue, and measures of heart muscle function. Findings describe patterns observed in the studies related to biochemical measurements, where changes in plasma carnitine levels were monitored. However, for certain patient-reported outcomes describing perceived discomfort, such as fatigue and exercise capacity, the findings were mixed and often inconsistent across different trials.

What is Still Uncertain About Cartine Research

Key research limitations include the fact that for the rare metabolic indications, comparative evidence is lacking, and evidence quality varies across studies, often relying on observational data due to ethical concerns. For the more common indications like secondary deficiency in ESRD, although numerous trials were conducted, the follow-up durations were limited in many RCTs, indicating that there is limited information for long-term outcomes and no research data that predict whether an individual will respond similarly based on available study results.

Key Studies & References

1. Carnitine Supplementation in Chronic Hemodialysis Patients—A Literature Review (MDPI)

Common questions about Cartine (FAQ)

---

Q: Is fatigue a possible side effect of Cartine?

Official side effect profiles primarily list gastrointestinal issues and effects on the nervous and musculoskeletal systems. However, studies examining the use of Cartine in patients on hemodialysis have specifically explored its effect on reported chronic fatigue and muscle strength measurements.

---

Q: Are there any food restrictions mentioned in the information for Cartine?

Official regulatory guidelines for the oral forms state that the medicine should be consumed during or following meals. This administration timing rule is stated in the official guidelines.

---

Q: Are there any specific organs or body systems Cartine is known to affect?

The medicine's core function is focused on supporting energy production, particularly in tissues with high energy demands like the cardiac and skeletal muscle. Additionally, official reporting on adverse events most frequently involves the gastrointestinal system, and effects on the nervous and musculoskeletal systems are also documented.

---

Q: Can Cartine be used by people with kidney issues?

According to official information, use is conditional for those with severe kidney issues. Official labeling permits the use of the injectable form for patients on long-term dialysis. However, chronic high oral doses are typically not recommended for individuals with severe renal impairment due to a documented risk of inactive metabolite accumulation.

---

Q: Why does the official leaflet mention a risk of a specific side effect?

The warnings in the official product information reflect documented safety observations related to specific patient groups. For example, a risk of increased seizure activity is noted because the medicine may have a potential to worsen pre-existing seizure conditions in some patients.

---

Q: Does Cartine require regular monitoring during its use?

Yes, the official protocol for use requires periodic measurement of certain markers, including plasma free carnitine concentrations and blood chemistries. This monitoring is required to track tolerance and provide information for adjusting the individualized dosage.

---

Q: Are there special considerations for using Cartine if someone is pregnant?

Regulatory documents indicate that use during pregnancy is only permitted if clearly needed, as adequate human studies are lacking to fully establish effects. Furthermore, official information documents that nursing mothers must consider the potential risks to the child versus the benefits of treatment when breastfeeding.

---

Q: Does the medication guide for Cartine mention any rare but serious concerns?

Yes, the official labeling includes reports of serious events. These documented concerns include the potential for serious hypersensitivity reactions (severe allergic responses) and reported changes in seizure activity, especially in patients with a pre-existing history of seizure disorder.

---

Q: Is the long-term safety profile of Cartine well established?

The official information describes the usage as a long-term protocol, but specific data points must be considered. Regulatory reports note a risk associated with the chronic oral administration of high doses in patients with severe kidney issues, and some clinical trials for certain indications have had limited follow-up durations for assessing long-term outcomes.

---

Q: What factors might influence the way Cartine works for a person?

Official guidance emphasizes that the medicine's effectiveness depends on the patient's underlying metabolic condition and adherence to the necessary monitoring and individualized dosing protocol. The drug is intended to facilitate the crucial transport of long-chain fatty acids for energy production.

---

Q: Can Cartine affect laboratory test results?

Official protocol requires the periodic measurement of plasma carnitine concentrations and blood chemistries to monitor treatment. Additionally, a documented interaction with coumarinic anticoagulants necessitates monitoring the International Normalized Ratio (INR), a measure of blood clotting.

---

Q: Is it possible to use Cartine with other prescribed medications?

Yes, it is possible to use Cartine with other prescribed medicines, but certain pharmacodynamic interactions are documented in official sources. These interactions require close monitoring, specifically when used alongside coumarinic anticoagulants or medicines used to manage blood glucose levels.

---

Q: Can Cartine be taken long-term?

The usage of Cartine for its approved indications is generally described as a long-term protocol. Treatment duration may be chronic, especially for inherited metabolic conditions or in patients receiving long-term dialysis.

---

Q: What happens if I miss a scheduled time to use Cartine?

Official regulatory guidance indicates that a missed dose may be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the labeling describes skipping the missed dose to avoid taking the doses too close together.

---

Q: Does Cartine have an impact on sleep?

The official adverse reaction profile does not explicitly list insomnia or somnolence. However, some documented effects on the Nervous System include reports of dizziness and headache, which are conditions that could indirectly affect sleep quality.

---

Q: How is the research evidence for Cartine typically described?

Official documents describe the supporting evidence using various types of studies, including Randomized Controlled Trials (RCTs) for more common indications and case reports/series for rare metabolic disorders. Summaries of the evidence sometimes note that findings for certain patient outcomes have been mixed or inconsistent across different trials.

---

Q: What is the general expectation for the duration of Cartine use?

Official documents describe the therapy as a long-term protocol designed to correct a specific carnitine deficiency. For inherited metabolic disorders and patients undergoing chronic dialysis, the duration of treatment is often expected to be chronic.

---

Q: Does Cartine have any warnings related to driving or operating machinery?

The official adverse reaction profile includes reports of conditions like seizures and dizziness. Because these documented effects may impair physical and mental abilities, official information notes that patients must be aware of this potential when driving or operating machinery.

---

Q: Is Cartine a controlled substance?

The pharmaceutical formulation of the active ingredient, Levocarnitine (Cartine), is not classified as a controlled substance under the US federal scheduling system.

---

Q: Is Cartine available over-the-counter anywhere?

The FDA-approved pharmaceutical formulations of the drug are available by prescription only for the treatment of documented carnitine deficiency. However, the active ingredient, L-carnitine, is also widely available in non-pharmaceutical forms sold as dietary supplements.

---

Q: Does Cartine have a classification for safety in children?

Official labeling confirms that use is established and permitted across all age groups, including infants and children, for treating documented carnitine deficiencies. The labeling provides details on specific administration and monitoring protocols for pediatric use.

The storage and disposal of Cartine (levocarnitine) must strictly follow official regulatory instructions, which vary by formulation.

Official Storage and Handling Requirements

• Temperature: Store most formulations at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Liquid forms must avoid excessive heat and be protected from freezing.
• Packaging and Protection: Tablets must remain in the original container due to their moisture-sensitive (hygroscopic) nature. Injection vials and oral solution containers must be stored in the outer carton to protect from light.
• Stability After Opening: The Oral Solution must be discarded after 30 to 60 days of first opening, as specified in the product labeling.

Disposal and Safety

All forms must be kept out of the reach of children. Unused or expired medicine should be disposed of via a drug take-back program or mixed with an undesirable substance and placed in the trash, with disposal adhering to local requirements for pharmaceutical waste.